SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Latigo Biotherapeutics, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

(CUSIP Number)

09/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- ☐ Rule 13d-1(b)
- ☐ Rule 13d-1(c)
- ☑ Rule 13d-1(d)

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons 5AM Ventures VI, L.P.	
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☑ (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization DELAWARE	
Number of Shares Beneficially	5	Sole Voting Power 0.00

Owned by Each Reporting Person With:	6	Shared Voting Power 4,975,543.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 4,975,543.00
9		Aggregate Amount Beneficially Owned by Each Reporting Person 4,975,543.00
10		Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐
11		Percent of class represented by amount in row (9) 7.5 %
12		Type of Reporting Person (See Instructions) PN

SCHEDULE 13G

CUSIP No.

1		Names of Reporting Persons 5AM Partners VI, LLC
2		Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☑ (b)
3		Sec Use Only
4		Citizenship or Place of Organization DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 4,975,543.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 4,975,543.00
9		Aggregate Amount Beneficially Owned by Each Reporting Person 4,975,543.00
10		Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐
11		Percent of class represented by amount in row (9) 7.5 %

12 Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP No.

1 Names of Reporting Persons

5AM Opportunities II, L.P.

2 Check the appropriate box if a member of a Group (see instructions)

☐ (a)
☑ (b)

3 Sec Use Only

4 Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5 Sole Voting Power

0.00

6 Shared Voting Power

2,350,419.00

7 Sole Dispositive Power

0.00

8 Shared Dispositive Power

2,350,419.00

9 Aggregate Amount Beneficially Owned by Each Reporting Person

2,350,419.00

10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

☐

11 Percent of class represented by amount in row (9)

3.5 %

12 Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP No.

1 Names of Reporting Persons

5AM Opportunities II (GP), LLC

2 Check the appropriate box if a member of a Group (see instructions)

☐ (a)
☑ (b)

3	Sec Use Only	
4	Citizenship or Place of Organization	
	DELAWARE	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 2,350,419.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 2,350,419.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person	
	2,350,419.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)	
	☐	
11	Percent of class represented by amount in row (9)	
	3.5 %	
12	Type of Reporting Person (See Instructions)	
	OO	

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons	
	Kush Parmar	
2	Check the appropriate box if a member of a Group (see instructions)	
	☐ (a) ☑ (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization	
	UNITED STATES	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 7,325,962.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 7,325,962.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person	

	7,325,962.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)	☐
11	Percent of class represented by amount in row (9)	11.0 %
12	Type of Reporting Person (See Instructions)	IN

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons	Andrew J. Schwab
2	Check the appropriate box if a member of a Group (see instructions)	☐ (a) ☑ (b)
3	Sec Use Only	
4	Citizenship or Place of Organization	UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:	5 Sole Voting Power	0.00
	6 Shared Voting Power	7,325,962.00
	7 Sole Dispositive Power	0.00
	8 Shared Dispositive Power	7,325,962.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person	7,325,962.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)	☐
11	Percent of class represented by amount in row (9)	11.0 %
12	Type of Reporting Person (See Instructions)	IN

SCHEDULE 13G

Item 1.

(a) Name of issuer:

Latigo Biotherapeutics, Inc.

(b) Address of issuer's principal executive offices:

c/o Latigo Biotherapeutics, Inc., 1300 Rancho Conejo Blvd., Suite 305, Thousand Oaks, CA, 91320.

Item 2.

Name of person filing:

(a) The names of the persons filing this report (collectively, the "Reporting Persons") are: 5AM Ventures VI, L.P. ("Ventures VI") 5AM Partners VI, LLC ("Partners VI") 5AM Opportunities II, L.P. ("Opps II") 5AM Opportunities II (GP), LLC ("Opps II GP") Kush Parmar ("Dr. Parmar") Andrew J. Schwab ("Schwab") The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.

(b) Address or principal business office or, if none, residence:

c/o 5AM Ventures 4 Embarcadero Center, Suite 3110 San Francisco, CA 94111

(c) Citizenship:

Ventures VI Delaware Partners VI Delaware Opps II Delaware Opps II GP Delaware Dr. Parmar United States Schwab United States

(d) Title of class of securities:

Common Stock, $0.0001 par value per share

(e) CUSIP No.:

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e) ☐ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) ☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) ☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:

(k) ☐ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4. Ownership

Amount beneficially owned:

(a) Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2026 and is incorporated by reference. The Reporting Persons' ownership of the Issuer's securities consists of (i) 4,975,543 shares of common stock held directly by Ventures VI; and (ii) 2,350,419 shares of common stock held directly by Opps II. Partners VI is the sole general partner of Ventures VI and Dr. Parmar and Schwab are the managing members of Partners VI. Each of Partners VI, Dr. Parmar and Schwab shares voting and dispositive power over the securities held by Ventures VI. Opps II GP is the sole general partner of Opps II and Dr. Parmar and Schwab are the managing members of Opps II GP. Each of Opps II GP, Dr. Parmar and Schwab shares voting and dispositive power over the securities held by Opps II.

Percent of class:

(b) Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentage of the shares of common stock of the Issuer beneficially owned by such Reporting Person as of September 30, 2026 and is incorporated by reference. The percentage set forth in each row 11 is based upon 66,299,347 shares of common stock outstanding as of September 1, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on September 3, 2026. %

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

Row 5 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2026 and is incorporated by reference.

(ii) Shared power to vote or to direct the vote:

Row 6 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2026 and is incorporated by reference.

(iii) Sole power to dispose or to direct the disposition of:

Row 7 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2026 and is incorporated by reference.

(iv) Shared power to dispose or to direct the disposition of:

Row 8 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2026 and is incorporated by reference.

Item 5. Ownership of 5 Percent or Less of a Class.

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable

Item 8. Identification and Classification of Members of the Group.
Not Applicable

Item 9. Notice of Dissolution of Group.
Not Applicable

Item 10. Certifications:
Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

5AM Ventures VI, L.P.

Signature: /s/ Andrew J. Schwab
Name/Title: By 5AM Partners VI, LLC, its General Partner, By Andrew J. Schwab, Managing Member
Date: 11/16/2026

5AM Partners VI, LLC

Signature: /s/ Andrew J. Schwab
Name/Title: By Andrew J. Schwab, Managing Member
Date: 11/16/2026

5AM Opportunities II, L.P.

Signature: /s/ Andrew J. Schwab
Name/Title: By 5AM Opportunities II (GP), LLC, its General Partner, By Andrew J. Schwab, Managing Member
Date: 11/16/2026

5AM Opportunities II (GP), LLC

Signature: /s/ Andrew J. Schwab
Name/Title: By Andrew J. Schwab, Managing Member
Date: 11/16/2026

Kush Parmar

Signature: /s/ Kush Parmar
Name/Title: Kush Parmar
Date: 11/16/2026

Andrew J. Schwab

Signature: /s/ Andrew J. Schwab
Name/Title: Andrew J. Schwab
Date: 11/16/2026

Exhibit Information

Exhibit 99.1 Joint Filing Agreement

EXHIBIT 99.1

JOINT FILING AGREEMENT

The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the common stock of Latigo Biotherapeutics, Inc. shall be filed on behalf of each of the undersigned and that this Joint Filing Agreement shall be filed as an exhibit to such Schedule 13G.

Dated: November 16, 2026

5AM Ventures VI, L.P.

By: 5AM Partners VI, LLC
its General Partner

By: /s/ Andrew J. Schwab
Name: Andrew J. Schwab
Title: Managing Member

5AM Partners VI, LLC

By: /s/ Andrew J. Schwab
Name: Andrew J. Schwab
Title: Managing Member

5AM Opportunities II, L.P.

By: 5AM Opportunities II (GP), LLC
its General Partner

By: /s/ Andrew J. Schwab
Name: Andrew J. Schwab
Title: Managing Member

5AM Opportunities II (GP), LLC

By: /s/ Andrew J. Schwab
Name: Andrew J. Schwab
Title: Managing Member

/s/ Dr. Kush Parmar
Dr. Kush Parmar

/s/ Andrew J. Schwab
Andrew J. Schwab